Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Jetstar to Charge for Overhead Cabin Bags From February 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Apple Restores Telegram to App Store After Content Policy Violation 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Telegram Restored on Apple App Store After Temporary Removal 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
WINDSOR, Conn., March 26, 2018 -- Scapa Healthcare, a trusted strategic outsource partner of skin-friendly, turnkey solutions, today announced the acquisition of Dallas, TX-based BioMed Laboratories. BioMed is a leading business-to-business developer and manufacturer of topical skin care solutions for advanced wound care, ostomy and consumer wellness markets.
Serving similar customer bases, BioMed is Scapa Healthcare’s first adjacent platform. The acquisition broadens Scapa’s offerings beyond adhesive-based solutions to now include complementary skin care offerings such as tubed hydrogel, wound cleansers, moisturizers and more. BioMed’s portfolio of products includes gels, creams, lotions, liquids, powders and hot fill waxes.
The addition of BioMed strengthens Scapa Healthcare’s offerings to its customers in the advanced wound care and ostomy markets, and expands market accessibility within consumer wellness segments such as OTC, first aid and health and beauty.
“At Scapa Healthcare, we remain committed to being the trusted strategic outsource partner of choice for our customers,” said Joe Davin, President Scapa Healthcare. “The acquisition of BioMed is in line with our continued growth strategy. We continue to expand our capabilities and product offerings while maintaining the level of excellence our partners expect.”
BioMed’s quality system is certified to ISO 13485 standards, and complies with FDA cGMP, Health Canada and EU regulatory requirements.
For more information on the acquisition, please visit http://www.scapa.com/en/news/AcquisitionofBioMedLaboratoriesLLC.
Learn more about BioMed Laboratories
About Scapa Healthcare
Scapa Healthcare is a global trusted strategic outsource partner of skin-friendly turnkey solutions for advanced wound care, consumer wellness and medical device markets. Scapa Healthcare partners with market leaders to design, develop, manufacture and commercialize innovative skin contact solutions to meet end-user needs. Scapa Healthcare offers turn-key development services, including design and project management; coating; converting, perforation and assembly; printing and packaging; and sterilization services. For more information, visit: www.scapahealthcare.com
Media Contact Jordan Bouclin SVM Public Relations and Marketing Communications [email protected] (401) 490-9700 Scapa Healthcare Contact Scapa Healthcare Marketing Communications Manager [email protected] (860) 902-8157
